Wavelength takes majority stake in Vanamali to strengthen drug substance manufacturing

API manufacturer says acquisition is next step of investment strategy to closely align API supply to customer needs in an unpredictable world

Vanamali manufacturers pharmaceutical key starting materials and advanced drug intermediates, and also has R&D capabilities.

Financial details of the transaction were not disclosed.

Wavelength CEO, Iftach Seri, said the acquisition represented the next stage of an investment strategy in which API supply was closely aligned with customer needs.

“These include planning for an increasingly unpredictable world, where supply chain assurance and control of regulatory starting materials further back in the process have become a key strategic concern,” he added.

In a statement, Wavelength said Vanamali provides customized process development and manufacturing services using advanced technologies and a quality-by-design approach to deliver eco-efficient regulatory compliant chemistry.

“Its researchers are skilled in managing process development, optimization and scale-up, and the company’s modern manufacturing facilities can deliver small research quantities up to multi-ton commercial-scale production runs,” Wavelength said.